Trilateral retinoblastoma

Trilateral Retinoblastoma is a rare, aggressive form of retinoblastoma, a cancer that begins in the retina, the light-sensitive lining on the inside of the eye. Trilateral retinoblastoma is characterized by the presence of bilateral retinoblastoma (tumors in both eyes) along with a neuroblastic tumor in the brain, typically in the pineal gland or parasellar region, leading to its designation as "trilateral." This condition represents a significant challenge in pediatric oncology due to its aggressive nature and the complexity of treatment required.

Etiology and Pathogenesis

Trilateral retinoblastoma is closely associated with mutations in the RB1 gene, which plays a crucial role in cell cycle regulation and tumor suppression. Inherited mutations in RB1 significantly increase the risk of developing retinoblastoma. In the case of trilateral retinoblastoma, the same genetic predisposition affects not only the retinas but also predisposes the pineal gland or parasellar region of the brain to develop neuroblastic tumors.

Clinical Presentation

Patients with trilateral retinoblastoma typically present with symptoms related to both the intraocular tumors and the intracranial tumor. Symptoms may include:

• Decreased vision or blindness
• A white color in the pupil when light is shone in the eye (leukocoria)
• Eye redness and irritation
• Differing eye colors or a visible tumor in the eye
• Symptoms related to increased intracranial pressure such as headache, vomiting, and lethargy, which are indicative of the presence of a brain tumor

Diagnosis

Diagnosis of trilateral retinoblastoma involves a comprehensive clinical evaluation, including:

• Detailed family and medical history
• Ophthalmologic examination to assess the intraocular tumors
• Imaging studies such as MRI or CT scans to identify and characterize the intracranial tumor
• Genetic testing for mutations in the RB1 gene

Treatment

Treatment of trilateral retinoblastoma is multidisciplinary, involving a combination of:

• Chemotherapy to reduce the size of the tumors
• Radiation therapy for local control, especially for the intracranial tumor
• Surgery for tumor removal when feasible
• Laser therapy or cryotherapy for smaller retinal tumors

Due to the complexity and aggressiveness of trilateral retinoblastoma, treatment plans are highly individualized and require coordination among specialists in oncology, ophthalmology, neurosurgery, and genetics.

Prognosis

The prognosis for trilateral retinoblastoma is generally poor, with a high mortality rate. Early detection and aggressive treatment are critical for improving outcomes. Long-term follow-up is necessary for survivors, as they are at increased risk for secondary cancers and other health issues related to their treatment.

Epidemiology

Trilateral retinoblastoma is extremely rare, accounting for a small percentage of all retinoblastoma cases. The exact incidence is difficult to determine due to its rarity.

Prevention and Screening

For families with a known RB1 mutation, genetic counseling and early screening of at-risk children are essential for early detection and treatment of retinoblastoma. Regular eye examinations and monitoring for symptoms of an intracranial tumor can aid in early diagnosis and treatment.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian